Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Equity Ratio (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Equity Ratio for 7 consecutive years, with 2.23 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 40.59% to 2.23 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.23 through Dec 2025, down 40.59% year-over-year, with the annual reading at 2.23 for FY2025, 40.59% down from the prior year.
  • Equity Ratio hit 2.23 in Q4 2025 for BridgeBio Pharma, down from 1.94 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.36 in Q1 2021 to a low of 2.68 in Q2 2023.
  • Historically, Equity Ratio has averaged 1.56 across 5 years, with a median of 1.62 in 2025.
  • Biggest five-year swings in Equity Ratio: plummeted 666.85% in 2021 and later soared 49.19% in 2024.
  • Year by year, Equity Ratio stood at 0.86 in 2021, then plummeted by 133.12% to 2.0 in 2022, then fell by 23.17% to 2.46 in 2023, then surged by 35.49% to 1.59 in 2024, then crashed by 40.59% to 2.23 in 2025.
  • Business Quant data shows Equity Ratio for BBIO at 2.23 in Q4 2025, 1.94 in Q3 2025, and 1.65 in Q2 2025.